AMC303

amcure GmbH · Phase 1 active Small molecule

At a glance

Generic name	AMC303
Also known as	CD44v6 inhibitor
Sponsor	amcure GmbH
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Safety and Pharmacokinetic Phase I/Ib Study of AMC303 in Patients With Solid Tumours (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AMC303 CI brief — competitive landscape report
AMC303 updates RSS · CI watch RSS
amcure GmbH portfolio CI